Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.08 USD | -0.49% | -8.11% | -20.62% |
Business Summary
Number of employees: 37
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Central Nervous System Therapies
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -120.50% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -120.50% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shawn Singh
CEO | Chief Executive Officer | 61 | 99-12-31 |
Cynthia Anderson
DFI | Director of Finance/CFO | 55 | 23-08-20 |
Joshua Prince
COO | Chief Operating Officer | 54 | 21-10-31 |
Ross Baker
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-30 |
Ann Cunningham
BRD | Director/Board Member | 56 | 19-01-09 |
Mark McPartland
IRC | Investor Relations Contact | 58 | 16-10-03 |
Jessica Haskell
SEC | Corporate Secretary | - | 22-07-31 |
Human Resources Officer | - | 21-12-31 | |
Erik Berglund
LAW | General Counsel | - | 21-01-31 |
Louis Monti
PRN | Corporate Officer/Principal | - | 20-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Saxe
BRD | Director/Board Member | 88 | 00-05-31 |
Jerry Gin
BRD | Director/Board Member | 81 | 16-02-29 |
Shawn Singh
CEO | Chief Executive Officer | 61 | 99-12-31 |
Chairman | 58 | 21-07-20 | |
Ann Cunningham
BRD | Director/Board Member | 56 | 19-01-09 |
Joanne Curley
BRD | Director/Board Member | 56 | 21-04-22 |
Mary Rotunno
BRD | Director/Board Member | 64 | 21-07-05 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 27,029,731 | 26,971,854 ( 99.79 %) | 4,522 ( 0.0167 %) | 99.79 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.62% | 110M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
0.00% | 21.78B | |
-9.33% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- VTGN Stock
- Company Vistagen Therapeutics, Inc.